OncoMatch/Clinical Trials/NCT04943848
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Is NCT04943848 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including rHSC-DIPGVax and Balstilimab for diffuse intrinsic pontine glioma.
Treatment: rHSC-DIPGVax · Balstilimab · Zalifrelimab — This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Biomarker criteria
Required: H3F3A (H3 K27M) K27M
Histone mutation must be confirmed by pathology report
Prior therapy
Must have received: radiation therapy
Must start radiation therapy within 42 days from date of diagnostic imaging
Cannot have received: cytotoxic chemotherapy
Exception: except for radiation
Subjects who have received any cancer therapy except for radiation
Cannot have received: alkylating agent (temozolomide)
Patients CANNOT receive temozolomide during radiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Health Orange County (CHOC) · Orange, California
- Ann and Robert H. Lurie Children's Hospital of Chicago · Chicago, Illinois
- Dana-Farber Boston Children's Cancer and Blood Disorders Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify